NCT00372385

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects With Hepatitis C

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 334 (actual)
• Sponsor: Vertex Pharmaceuticals Incorporated · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels

Conditions

• Chronic Hepatitis C

Interventions

Type	Name	Description
DRUG	Ribavirin	tablet
DRUG	Pegylated Interferon Alfa 2a	Solution for injection
DRUG	Placebo	tablet
DRUG	Telaprevir	tablet

Timeline

• Start date: 2006-08-01
• Primary completion: 2008-05-01
• Completion: 2008-06-01
• First posted: 2006-09-06
• Last updated: 2014-07-23
• Results posted: 2011-07-21

Locations

4 sites across 4 countries: Austria, France, Germany, United Kingdom